A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
NCT #
NCT05934539
Condition(s)
Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Cancer, Urothelial Cancer
Molecular Target(s)
5T4, CD137
Drug Classification(s)
Bispecific Antibodies
Agents(s)
ALG.APV-527
Phase(s)
I
Mechanism of Action
ALG.APV-527 binds to both its targets, 4-1BB and 5T4. ALG.APV-527 has the potential to activate T cells and NK cells that are present in the TME in patients with various 5T4-expressing solid malignancies.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from ALG.APV527
- How the study agent is acting on your body
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.